Beyond MZE829, Maze's pipeline includes MZE782, an SLC6A19 inhibitor targeting chronic kidney disease and phenylketonuria, with Phase I data expected in the second half of 2025. Analysts view it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback